TL;DR
This paper details a Phase IIb clinical trial protocol for "Hanslim," a Korean herbal medicine, to assess its efficacy and safety in treating obesity. The study aims to establish an appropriate dosage for Hanslim by comparing it against a placebo in a randomized, double-blind, multicenter trial, paving the way for larger-scale Phase III trials.
What Problem Does This Paper Address?
Obesity is a global health crisis, linked to numerous serious medical complications like diabetes, hypertension, and cardiovascular disease. While some anti-obesity medications exist, they often come with significant side effects. This necessitates the development of safer and effective alternatives. Hanslim, a traditional Korean herbal formula, has shown promise in preclinical and retrospective studies for weight loss and improving metabolic markers. However, prospective clinical trials are needed to rigorously evaluate its efficacy and safety, and crucially, to determine the optimal dosage for clinical use.
Methods
This study employs a multicenter, randomized, double-blind, multidose, placebo-controlled, phase IIb clinical trial design. A total of 165 obese patients will be recruited and randomly assigned to one of three groups: high-dose Hanslim, low-dose Hanslim, or placebo, in a 1:1:1 ratio. Participants will receive 2 tablets of either Hanslim or placebo twice daily for 12 weeks. The study protocol includes scheduled visits for assessments and data collection.
Key methodological aspects include:
- Randomization and Allocation Concealment: An independent statistician will generate random numbers, and participants will be given identically packaged, consecutively numbered drug containers to maintain blinding.
- Blinding: Participants, outcome assessors, study monitors, data managers, and statisticians will be blinded to the treatment allocation. Emergency codes will be available for critical situations.
- Intervention: Hanslim tablets are standardized to contain specific amounts of Ephedra extract, Gypsum fibrosum, Atractylodes lancea, and Thea sinensis. The high-dose tablet contains 480 mg of dried herbal extract, while the low-dose tablet contains 240 mg. Placebo tablets are designed to be indistinguishable from Hanslim tablets in appearance.
- Outcome Measurement: The primary efficacy outcome is the proportion of participants achieving more than 5% weight loss from baseline after 12 weeks. Secondary outcomes include changes in body weight, BMI, body-fat percentage, waist circumference, serum lipids, blood glucose, and quality of life scores. Safety will be assessed through vital signs, physical examinations, laboratory tests, and adverse event monitoring.
Datasets
Not discussed in the paper. The study relies on data collected from participants enrolled in the clinical trial.
Key Insights and Ideas
- Bridging Traditional Medicine and Modern Clinical Trials: The study represents a significant effort to rigorously evaluate a traditional herbal medicine (Hanslim) using modern, evidence-based clinical trial methodologies.
- Dosage Optimization is Crucial: A key focus is on determining the "appropriate dosage" of Hanslim, acknowledging that while herbal medicines can be effective, precise dosing is essential for both efficacy and safety, especially when dealing with potent ingredients like Ephedra.
- Comprehensive Safety and Efficacy Assessment: The protocol outlines a thorough approach to evaluating both the positive effects (weight loss, metabolic improvements) and potential risks (adverse events, laboratory abnormalities) of Hanslim.
- Foundation for Larger Trials: This Phase IIb study is designed to provide the necessary evidence to justify and inform a larger, more definitive Phase III clinical trial, which is often a requirement for drug approval.
Key Results
As this is a study protocol, no results are presented. The paper outlines the planned methodology and expected outcomes. The primary outcome will be the difference in the proportion of participants achieving >5% weight loss between the Hanslim groups and the placebo group. Secondary outcomes will assess changes in various anthropometric and metabolic parameters. Safety will be evaluated by monitoring adverse events and laboratory results.
Limitations and Future Work
- Limitations:
- The study is a Phase IIb trial, meaning it is a preliminary investigation and not definitive proof of efficacy or safety.
- The protocol acknowledges the need for careful monitoring of adverse events, particularly given the inclusion of Ephedra, which has known side effects.
- The study duration is 12 weeks, which may not capture long-term effects or sustainability of weight loss.
- Future Work:
- The successful completion of this study is intended to provide evidence for conducting a large-scale, phase III clinical trial.
- The results will be published in a peer-reviewed journal, contributing to the scientific literature on herbal treatments for obesity.
- Future research could explore the long-term efficacy and safety of Hanslim, as well as its mechanisms of action in more detail.
Summary updated